Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis

Future Oncol. 2017 May;13(11):1021-1034. doi: 10.2217/fon-2016-0428. Epub 2017 Jan 16.

Abstract

Aim: To assess the prognostic values of Ki-67 in neoadjuvant setting for breast cancer patients.

Methods: PubMed and EMBASE were searched. Revman software was used to conduct random-effect model meta-analysis.

Results: 49 studies (14,076 patients) were included. High Ki-67 before and after neoadjuvant chemotherapy were associated with worse overall survival (OS; before: hazard ratio [HR]: 2.29; 95% CI: 1.42-3.69; after: HR: 2.24; 95% CI: 1.82-2.75) and disease-free survival (DFS; before: HR: 1.54; 95% CI: 1.23-1.95; after: HR: 2.08; 95% CI: 1.83-2.37). Low/no reduction or increase might be associated with worse DFS (HR: 2.13; 95% CI: 1.51-3.02) and OS.

Conclusion: Ki-67 before and after neoadjuvant chemotherapy, as well as the change could predict the prognosis for breast cancer patients.

Keywords: Ki-67; disease-free survival; neoadjuvant chemotherapy; overall survival.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / mortality*
  • Female
  • Humans
  • Ki-67 Antigen / metabolism*
  • Neoadjuvant Therapy
  • Prognosis
  • Publication Bias
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Ki-67 Antigen